

# CITATION REPORT

List of articles citing

A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients

DOI: 10.2337/dc06-2001  
Diabetes Care, 2007, 30, 1480-6.

**Source:** <https://exaly.com/paper-pdf/41729069/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
66	Management approaches for pediatric obesity. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2007</b> , 3, 810-8		26
65	Increased propensity for calcium phosphate kidney stones with topiramate use. <i>Expert Opinion on Drug Safety</i> , <b>2007</b> , 6, 547-57	4.1	45
64	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2008</b> , 17, i-xii	2.6	
63	Current literature in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2008</b> , 24, i-x	7.5	
62	Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. <i>CNS Neuroscience and Therapeutics</i> , <b>2008</b> , 14, 120-42	6.8	94
61	Topiramate and type 2 diabetes: an old wine in a new bottle. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 81-90	6.4	13
60	Antiepileptic Drugs in Obesity, Psychotropic-Associated Weight Gain, and Eating Disorders. <i>Medical Psychiatry</i> , <b>2008</b> , 283-310		1
59	Drugs in the pipeline for the obesity market. <i>Journal of Diabetes Science and Technology</i> , <b>2008</b> , 2, 913-8	4.1	25
58	American College of Endocrinology Pre-Diabetes Consensus Conference: part two. <i>Diabetes Care</i> , <b>2008</b> , 31, 2222-9	14.6	4
57	Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedication, and comorbid substance use. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 125-31	1.7	20
56	Emerging therapies for metabolic diseases--the focus is on diabetes and obesity. <i>Current Opinion in Chemical Biology</i> , <b>2009</b> , 13, 332-7	9.7	24
55	Topiramate administration decreases body weight and preserves lean body mass in hemicranic women. <i>European E-journal of Clinical Nutrition and Metabolism</i> , <b>2009</b> , 4, e148-e151		2
54	Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. <i>Research in Developmental Disabilities</i> , <b>2009</b> , 30, 613-69	2.7	51
53	Pharmacotherapy for the obese patient. <i>Primary Care - Clinics in Office Practice</i> , <b>2009</b> , 36, 407-15	2.2	5
52	Combination therapy for obesity and metabolic disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2009</b> , 16, 353-8	4	24
51	Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 706-10	1.7	26
50	New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?. <i>Pharmacology Biochemistry and Behavior</i> , <b>2010</b> , 97, 63-83	3.9	56

49	Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. <i>Journal of Clinical Neuroscience</i> , <b>2010</b> , 17, 1256-9	2.2	8
48	Neuropsychiatric adverse effects of centrally acting antiobesity drugs. <i>CNS Neuroscience and Therapeutics</i> , <b>2011</b> , 17, 490-505	6.8	79
47	Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2011</b> , 377, 1341-52	4.0	611
46	Adrenal cushing syndrome shortly after Adrenal insufficiency. <i>Endocrine Practice</i> , <b>2011</b> , 17, 656-661	3.2	
45	Predictors of weight loss and maintenance in patients treated with antiobesity drugs. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2011</b> , 4, 229-43	3.4	11
44	Pharmacotherapies for obesity: past, current, and future therapies. <i>Journal of Obesity</i> , <b>2011</b> , 2011, 1796-7	3.4	110
43	Contemporary approaches to adult obesity treatment. <i>Nurse Practitioner</i> , <b>2011</b> , 36, 37-46	0.4	2
42	Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. <i>Obesity Reviews</i> , <b>2011</b> , 12, e338-47	10.6	180
41	Nephrolithiasis in topiramate users. <i>Urological Research</i> , <b>2011</b> , 39, 303-7		31
40	Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. <i>American Journal of Clinical Nutrition</i> , <b>2012</b> , 95, 297-308	7	430
39	A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. <i>Sleep</i> , <b>2012</b> , 35, 1529-39	1.1	82
38	What is the prognosis for new centrally-acting anti-obesity drugs?. <i>Neuropharmacology</i> , <b>2012</b> , 63, 132-46	5.5	49
37	Phentermine and topiramate extended release (Qsymia) first global approval. <i>Drugs</i> , <b>2012</b> , 72, 2033-42	12.1	21
36	Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women. <i>European Journal of Endocrinology</i> , <b>2012</b> , 167, 839-45	6.5	4
35	The potential role of glutamate in the current diabetes epidemic. <i>Acta Diabetologica</i> , <b>2012</b> , 49, 167-83	3.9	30
34	Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. <i>Acta Diabetologica</i> , <b>2012</b> , 49, 75-9	3.9	9
33	An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus. <i>Clinical Drug Investigation</i> , <b>2013</b> , 33, 929-38	3.2	3
32	Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. <i>Obesity</i> , <b>2013</b> , 21, 2163-71	8	133

31	A review of late-stage CNS drug candidates for the treatment of obesity. <i>International Journal of Obesity</i> , <b>2013</b> , 37, 107-17	5.5	13
30	Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 131-9	3.4	19
29	Pregabalin attenuates excitotoxicity in diabetes. <i>PLoS ONE</i> , <b>2013</b> , 8, e65154	3.7	6
28	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 809-22	4	20
27	Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 1178-88	1.9	47
26	Antiepileptic drugs and hormones. 65-79		
25	Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism. <i>Experimental and Clinical Psychopharmacology</i> , <b>2014</b> , 22, 419-23	3.2	4
24	Weight management in type 2 diabetes: current and emerging approaches to treatment. <i>Diabetes Care</i> , <b>2015</b> , 38, 1161-72	14.6	129
23	Improvement in chronic low back pain in an obese patient with topiramate use. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , <b>2015</b> , 29, 140-3	0.8	1
22	Combination phentermine and topiramate extended release in the management of obesity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1263-74	4	18
21	A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 53-65	1.9	10
20	Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans Cell Mass and Function. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 756-67	7	25
19	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. <i>Endocrine Practice</i> , <b>2016</b> , 22 Suppl 3, 1-203	3.2	557
18	Cardiovascular Effects of the New Weight Loss Agents. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 849-59	15.1	16
17	Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 114, 9-14	7.4	8
16	Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1295-1305	6.7	71
15	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. <i>Current Diabetes Reports</i> , <b>2017</b> , 17, 34	5.6	28
14	Select medications that unexpectedly lower HbA1c levels. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 587-590	2.2	

13	GABA and Glutamate: Their Transmitter Role in the CNS and Pancreatic Islets. <b>2018</b> ,		4
12	The pharmacotherapeutic management of obstructive sleep apnea. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1981-1991	4	4
11	Synchronous neuronal interactions in rat hypothalamic culture: a novel model for the study of network dynamics in metabolic disorders. <i>Experimental Brain Research</i> , <b>2021</b> , 239, 755-764	2.3	1
10	The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings. <i>Current Obesity Reports</i> , <b>2021</b> , 10, 396-408	8.4	4
9	Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. <i>Clinical Schizophrenia and Related Psychoses</i> , <b>2013</b> , 6, 186-96	1.6	16
8	Phentermine, sibutramine and affective disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2013</b> , 11, 7-12	3.4	5
7	Obesity. <b>2010</b> , 99-114.e4		
6	References. <b>2011</b> , 283-360		
5	Assessment of the Obese Patient. <b>2014</b> , 167-187		
4	Drugs for Weight Loss and Maintenance: Present and Future. <b>2014</b> , 225-245		
3	Assessment of the Obese Patient. <b>2014</b> , 167-187		0
2	Drugs for Weight Loss and Maintenance: Present and Future. <b>2014</b> , 225-245		0
1	The effect of topiramate on weight loss in patients with type 2 diabetes. <i>Journal of Research in Medical Sciences</i> , <b>2013</b> , 18, 297-302	1.6	9